Abstract:Background: There is an unmet need for a minimally invasive clinical test using samples collected by medical staff or by self-collection to screen persons for Alzheimer's disease (AD), Parkinson's Disease (PD) and other dementias and diseases. AD is underdiagnosed today, particularly in underserved populations where it is high incidence (non-Hispanic black and Hispanic) and in rural populations. Even in populations with access to health care, diagnosis is often delayed by years, even though the most recently approved therapies are most efficacious when given early in the progression of disease. While dementias are diseases of the brain, many publications link the underpinning inflammatory aspects to circulating neutrophils, macrophages, and lymphocytes. Thus, there is an opportunity to exploit the hematologic aspects of AD and PD in its diagnosis and potentially, therapeutically. AD gene expression signatures using RNA extracted from venipuncture whole blood have been reported. FDA-cleared tests based on circulating biomarkers are in use today but are not definitive tests for AD. We developed a direct, extraction-free TempO-Seq® assay of gene expression using blood from a finger prick spotted on filter paper, providing a simple and minimally invasive method of obtaining a blood sample and performing a test that can potentially be used to identify a host of diseases and disease risk. We then implemented a test that classified patients as having AD or PD. Method: The commercial targeted sequencing whole transcriptome TempO-Seq® gene expression assay (Yeakley, PLosOne doi.org/10.1371/journal.pone.0178302) was adapted to utilize blood from a simple fingerstick spotted on filter paper and dried (not a biohazard, simplifying transport and testing). Three independent patient cohorts of samples (~50:50 male:female) were obtained from normal volunteers and patients clinically diagnosed with AD or PD based on cognitive testing. AD, PD, and used for training/retraining and testing/retesting AD and PD classification signatures. To account for the presence of subtypes in our dataset, we contrasted AD and control samples by testing hundreds of random subsets and performing differential gene expression analyses (DESeq2). We used machine learning approaches (k-nearest neighbors, random forest, support vector machine with either linear, polynomial or rgb kernel and extreme gradient boosting) to build algorithms differentiating control, AD and PD. Randomly sampled subsets accounting for 80% of each cohort were used to train these classifiers. The accuracy of calling AD and PD samples was determined using the remaining 20% of samples as a test set. For each classifier an area under ROC curve (AUC-ROC) was calculated. Gene set enrichment was performed using the Gene Ontology database for biological processes (p value threshold 0.05) to identify expressed pathways. Result: A protocol that eliminated interference by components of whole blood with enzymes used in molecular biology assays (including PCR) was successfully implemented. This permitted a TempO-Seq assay to be carried out without extraction of RNA from the filter paper blood spots. Highly expressed genes were attenuated to increase the sensitivity with which AD biomarker genes could be measured. Within-spot reproducibility (r>0.96) and day-to-day reproducibility of blood collected from the same donor (r>0.94) was excellent. The AUC-ROC for the AD classifier was 0.86, and for the PD classifier was 0.87. Predominate pathways were immune response pathways, with the three most significantly differentially expressed pathways related to the involvement of neutrophils in the immune and inflammatory response. Conclusion: Patients with AD and PD, and potentially other dementias and diseases, can be classifiedusing a TempO-Seq gene expression signature obtained from fingerstick blood spotted on filter paper. Such samples are easily collected by medical staff or by self-collection, potentially transforming the diagnosis of AD and PD, reducing health disparities, and by speeding up diagnosis, enabling therapy for many to begin earlier. The data support that neutrophils and immune cells either impact disease and/or are impacted by disease, consequently resulting in expression of disease signatures capable of classifying patients.

Abstract 5643: Targeted RNA-seq of dried blood microsamples for convenient RNA biomarker monitoring

Abstract 2302: Innovative blood-based cell-free RNA whole transcriptome sequencing for comprehensive RNA profiling in patient plasma samples and its clinical applications

Abstract 5605: Ambient storage and stabilization of proteins and cell-free nucleic acids in whole blood samples

Abstract 995: Preservation of patient whole blood preserves cancer immune cell biology at single cell resolution

Abstract 3794: Sensitive detection of microRNA biomarkers of pancreatic cancer using one-pot endonucleolytically exponentiated rolling circle amplification by CRISPR-Cas12a

Gene expression profiling of whole blood: Comparison of target preparation methods for accurate and reproducible microarray analysis

Abstract 6607: Dried blood spot (DBS) sample analysis for drug and metabolomic profiling in oncology clinical trials: Cost-effective decentralized sampling modality for precision oncology

Abstract 316: A novel, high-throughput full-length scRNA-seq workflow for improved biomarker discovery

Abstract LB-144: Molecular Signatures of Circulating Melanoma Cells for Monitoring Early Response to Immune Checkpoint Therapy

Abstract 6560: Cell-free RNA analysis for non-invasive cancer detection and characterization

Evaluation of low volume sampling devices for a pharmacodynamic biomarker analysis: Challenges and solutions

Abstract 7626: Assessment of precision melanoma diagnostics: Circulating microrna expression to monitor late-stage treatment

Abstract 5027: Simplified selective electrochemical detection of ctDNA differentiates between cancer progression and regression

Abstract 3670: Reducing the patient burden for ctDNA biomarkers: Advancing small volume home-based collection technologies

Diagnosis of Disease Using Whole Blood from a Fingerstick Spotted on Filter Paper: Gene Expression Signature Test for Alzheimer's and Parkinson's Diseases

Abstract 5791: Microfluidics-based library preparation strategies for targeted high-throughput sequencing and RNA sequencing in hematological malignancies in clinical samples

Abstract 3863: Flow cytometry using stabilized whole blood to assess innate and adaptive immune cells (Monocytes, NK, T, and B cells) in immunotherapies

Abstract 2039: Predicting abundance and expression of immune cells in patients’ head & neck tumor microenvironment from blood single-cell transcriptomics

Abstract 7611: Circulating blood RNAseq detects activation of immune system and predicts response to immunotherapy in bladder cancer

Choice of blood collection methods influences extracellular vesicles counts and miRNA profiling

Abstract 5018: Evaluation of whole blood fractionation conditions for optimal liquid biopsy NGS applications